Mitochondria are recognized as one of the most important targets for new drug design in
cancer, cardiovascular, and neurological diseases. Currently, the most effective way to …

The search for treatments for neurodegenerative diseases is a major concern in light of
today's aging population and an increasing burden on individuals, families, and society …

There are currently no effective biomarkers for diagnosing Parkinson's disease (PD) or
tracking its progression. Here, we developed an artificial intelligence (AI) model to detect PD …

We conducted a double-blinded phase I clinical trial to establish whether nicotinamide
adenine dinucleotide (NAD) replenishment therapy, via oral intake of nicotinamide riboside …

Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has
neuroprotective effects in preclinical models of Parkinson's disease. We investigated …

Abstract Objective The Parkinson's Progression Markers Initiative (PPMI) is an
observational, international study designed to establish biomarker‐defined cohorts and …

Aging-related, nonresolving inflammation in both the central nervous system (CNS) and
periphery predisposes individuals to the development of neurodegenerative disorders …

Transition‐metal dyshomeostasis is recognized as a critical pathogenic factor at the onset
and progression of neurodegenerative disorder (ND). Excess transition‐metal ions such as …

Axonal degeneration is responsible for disease progression and accumulation of disability
in many neurodegenerative conditions. The axonal degenerative process can generate a …

Axonal degeneration is an early and ongoing event that causes disability and disease
progression in many neurodegenerative disorders of the peripheral and central nervous …